These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25179838)

  • 1. Identification and clinical implications of circulating microRNAs for estrogen receptor-positive breast cancer.
    Park IH; Kang JH; Lee KS; Nam S; Ro J; Kim JH
    Tumour Biol; 2014 Dec; 35(12):12173-80. PubMed ID: 25179838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study.
    Kodahl AR; Lyng MB; Binder H; Cold S; Gravgaard K; Knoop AS; Ditzel HJ
    Mol Oncol; 2014 Jul; 8(5):874-83. PubMed ID: 24694649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer.
    McDermott AM; Miller N; Wall D; Martyn LM; Ball G; Sweeney KJ; Kerin MJ
    PLoS One; 2014; 9(1):e87032. PubMed ID: 24498016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study.
    Moi L; Braaten T; Al-Shibli K; Lund E; Busund LR
    J Transl Med; 2019 Oct; 17(1):334. PubMed ID: 31581940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO.
    Pizzamiglio S; Ciniselli CM; de Azambuja E; Agbor-Tarh D; Moreno-Aspitia A; Suter TM; Trama A; De Santis MC; De Cecco L; Iorio MV; Silvestri M; Pruneri G; Verderio P; Di Cosimo S
    Breast Cancer Res Treat; 2024 Jul; 206(2):285-294. PubMed ID: 38689174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
    Lowery AJ; Miller N; Devaney A; McNeill RE; Davoren PA; Lemetre C; Benes V; Schmidt S; Blake J; Ball G; Kerin MJ
    Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment.
    Hoppe R; Achinger-Kawecka J; Winter S; Fritz P; Lo WY; Schroth W; Brauch H
    Eur J Cancer; 2013 Nov; 49(17):3598-608. PubMed ID: 23968733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.
    Tian X; Zhang Z
    IUBMB Life; 2018 Jan; 70(1):71-80. PubMed ID: 29247596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA and LncRNA Expression Profiles in Human Estrogen Receptor Positive Breast Cancer.
    Shao X; Huang P; Shi L; Lei L; Cao W; Chen Z; Wang X; Zheng Y
    Clin Lab; 2019 Jan; 65(1):. PubMed ID: 30775882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
    Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H
    Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of Circulating MiR-21 Expression as a Potential Biomarker for Therapeutic Monitoring and Clinical Outcome in Breast Cancer.
    Anwar SL; Sari DNI; Kartika AI; Fitria MS; Tanjung DS; Rakhmina D; Wardana T; Astuti I; Haryana SM; Aryandono T
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1223-1228. PubMed ID: 31030498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of circulating microRNA signatures for breast cancer detection.
    Chan M; Liaw CS; Ji SM; Tan HH; Wong CY; Thike AA; Tan PH; Ho GH; Lee AS
    Clin Cancer Res; 2013 Aug; 19(16):4477-87. PubMed ID: 23797906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth.
    Leivonen SK; Sahlberg KK; Mäkelä R; Due EU; Kallioniemi O; Børresen-Dale AL; Perälä M
    Mol Oncol; 2014 Feb; 8(1):93-104. PubMed ID: 24148764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression.
    Eichelser C; Flesch-Janys D; Chang-Claude J; Pantel K; Schwarzenbach H
    Clin Chem; 2013 Oct; 59(10):1489-96. PubMed ID: 23748853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response.
    Xing AY; Wang B; Li YH; Chen X; Wang YW; Liu HT; Gao P
    Pathol Oncol Res; 2021; 27():1609753. PubMed ID: 34257614
    [No Abstract]   [Full Text] [Related]  

  • 16. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
    Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
    Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer.
    Cheng C; Fu X; Alves P; Gerstein M
    Genome Biol; 2009; 10(9):R90. PubMed ID: 19723326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
    Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
    Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
    Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.